IL316205A - Capsid variants and methods of using them - Google Patents

Capsid variants and methods of using them

Info

Publication number
IL316205A
IL316205A IL316205A IL31620524A IL316205A IL 316205 A IL316205 A IL 316205A IL 316205 A IL316205 A IL 316205A IL 31620524 A IL31620524 A IL 31620524A IL 316205 A IL316205 A IL 316205A
Authority
IL
Israel
Prior art keywords
methods
same
capsid variants
capsid
variants
Prior art date
Application number
IL316205A
Other languages
English (en)
Hebrew (he)
Inventor
Hanna Levitin
Heikki Turunen
Original Assignee
Dyno Therapeutics Inc
Hanna Levitin
Heikki Turunen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyno Therapeutics Inc, Hanna Levitin, Heikki Turunen filed Critical Dyno Therapeutics Inc
Publication of IL316205A publication Critical patent/IL316205A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL316205A 2022-04-15 2023-04-14 Capsid variants and methods of using them IL316205A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263331543P 2022-04-15 2022-04-15
US202363443262P 2023-02-03 2023-02-03
PCT/US2023/065815 WO2023201364A2 (en) 2022-04-15 2023-04-14 Capsid variants and methods of using the same

Publications (1)

Publication Number Publication Date
IL316205A true IL316205A (en) 2024-12-01

Family

ID=88330421

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316205A IL316205A (en) 2022-04-15 2023-04-14 Capsid variants and methods of using them

Country Status (10)

Country Link
US (1) US20250250305A1 (https=)
EP (1) EP4508064A2 (https=)
JP (1) JP2025512534A (https=)
KR (1) KR20250011900A (https=)
CN (1) CN119630688A (https=)
AU (1) AU2023253718A1 (https=)
CA (1) CA3255976A1 (https=)
IL (1) IL316205A (https=)
MX (1) MX2024012615A (https=)
WO (1) WO2023201364A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120699111B (zh) * 2025-08-26 2025-12-30 朗信启昇(苏州)生物制药有限公司 增强型aav载体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11021519B2 (en) * 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
US11364308B2 (en) * 2016-05-13 2022-06-21 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
JP2023535632A (ja) * 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Ｄｎａ分子の組成物、その作製方法、及びその使用方法
IL308987A (en) * 2021-06-03 2024-01-01 Dyno Therapeutics Inc Capsid variants and methods of using them

Also Published As

Publication number Publication date
US20250250305A1 (en) 2025-08-07
CN119630688A (zh) 2025-03-14
EP4508064A2 (en) 2025-02-19
KR20250011900A (ko) 2025-01-22
WO2023201364A2 (en) 2023-10-19
CA3255976A1 (en) 2023-10-19
MX2024012615A (es) 2025-02-10
JP2025512534A (ja) 2025-04-17
WO2023201364A3 (en) 2023-11-16
AU2023253718A1 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
IL308987A (en) Capsid variants and methods of using them
IL311871A (en) Capsid variants and methods of using them
IL299704A (en) Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using them
PT3872091T (pt) Anticorpos contra sars-cov-2
IL287720A (en) modulators of thr-in the cell and methods of using them
PL3983064T3 (pl) Modulatory cot i sposoby ich zastosowania
IL305834A (en) Phenalkylamines and methods for their preparation and use
IL314320A (en) Compounds and methods of use
IL304736A (en) Binders and methods of using them
IL315305A (en) Improved IgG-degrading enzymes and methods of using them
IL312466A (en) PI3K-alpha inhibitors and methods for their preparation and use
IL318393A (en) Azaquinazoline compounds and methods of use
IL287829A (en) Progranulin modulators and methods of using them
IL316205A (en) Capsid variants and methods of using them
GB2589398B (en) Compounds and methods of use
IL314277A (en) Anti-B7-H3 compounds and methods of use
IL286946A (en) enpp1 polypeptides and methods of using them
ZA202108165B (en) Application of kdm5a gene and atrx gene
HK40122659A (en) Capsid variants and methods of using the same
HK40114388A (en) Capsid variants and methods of using the same
AU2022296534A1 (en) Capsid variants and methods of using the same
EP4346767A4 (en) CAPSIDE VARIANTS AND METHODS OF USE THEREOF
IL312205A (en) Coxsackievirus B compounds and methods of using them
EP4496580A4 (en) MORRETON VIRUS AND METHODS OF USE
GB2625512B (en) Triggered-producer and triggered-consumer instructions